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ComplicationHyperammonemia is an uncommon side effect of topiramate (TPM) that has only been reportedwhen it is used as
an adjunct to valproate. We report a patient with mental retardation who developed reversible encephalopathy
from TPM. Ammonia level was monitored during the course of TPM treatment. This patient had recurring,
reversible elevations in serum ammonia levels that coincided with the administration of TPM. To our knowledge,
symptomatic hyperammonemia has not been reported to occur with TPM monotherapy.
© 2014 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Metabolic encephalopathy poses a challenging diagnosis to neurolo-
gists because of the condition's varied and potentially reversible etiolo-
gies. Drug-induced metabolic encephalopathies are common but often
go unrecognized. This is unfortunate as the correct identiﬁcation of
the cause and discontinuation of the offending agent usually result in
quick and complete resolution of the symptoms. As a group, antiepilep-
tic drugs are a relatively common cause of encephalopathy, either by
direct CNS effect, or, in some cases, by inducing hyperammonemia.
This is a well-established complication of valproic acid and has now
been reported to occur in patients previously treated with valproic
acid to which TPM was added [1–8]. Topiramate is a broad-spectrum
anticonvulsant that is also extensively used for migraine prophylaxis,
as a mood stabilizer, and for alcohol dependency.When given asmono-
therapy, the use of TPM can be associated with cognitive impairment,
glaucoma, and kidney stones. Hyperammonemia has not been reported
with the use of TPM monotherapy.2. Case
A 44-year-old Hispanic male with past medical history of mental re-
tardation, hypothyroidism, and depressive psychosis was admitted to
the hospital with a two-week history of altered mental status. The
etiology of developmental delay was related to birth-related problems.en access article under the CC BY-NCThere was no clinical or laboratory evidence of inborn errors of me-
tabolism. At baseline, the patient had moderate developmental delay
and was able to feed himself, use the restroom on his own, communi-
cate using a few words, and ambulate without assistance. Topiramate
100 mg bid had been started to treat mood disorder. Over a two-week
period preceding admission, he stopped talking and was noted to
have increasing gait instability and generalized weakness. He became
unable to feed himself and became incontinent of urine. Examination
on admission showed the patient to be lethargic but aroused. His
language output was limited to him repeating the words “ﬁne–ﬁne”
whenever he was asked a question. Cranial nerve exam was notable
for gaze-evoked nystagmus on lateral gaze bilaterally. The patient was
hyperreﬂexic with 3+ reﬂexes of all four extremities. He was ataxic
and had gait instability. No asymmetry of the motor exam and no
asterixis were observed.
The patient arterial ammonia was elevated at 77 μmol/l (upper limit
of normal= 60 μmol/l) on admission. The rest of the laboratory test re-
sults were normal including other liver function tests and hepatitis
panel. Electroencephalogram on admission showed generalized back-
ground slowing without triphasic waves or epileptiform discharge.
Brain MRI showed generalized brain atrophy without abnormalities in
the white matter or cortex. The initial diagnostic impression was
hyperammonemia-induced encephalopathy. He was treated with
lactulose, and TPM was discontinued on the ﬁrst day of admission. No
other medication changes were carried out. Within two days, mental
state changes resolved, and staff who were familiar with the patient
felt that hewas back to his baseline. Repeat ammonia level the following
day was 27 μmol/l. On the third day of admission, the patient had a-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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the right side of the face and the right arm. Topiramate was restarted at
the same dosage as before. The seizures did not reoccur, but repeat am-
monia levels over the ensuing two days showed a trend upwards,
47 μmol/l and 57 μmol/l, respectively. Given the fact that ammonia
levels were again elevated with TPM, it was switched to lamotrigine
(LTG). Twenty-four hours after the discontinuation of TPM, serum
ammonia again decreased to 33 μmol/l.
3. Discussion
Topiramate was originally synthesized as a potential hypoglycemic
agent [9]. Although the drug did not show hypoglycemic activity, it
showed a wide range of CNS effects, acting as an antagonist of voltage-
activated Na+ channels, L-type voltage-activated Ca2+ channels,
carbonic anhydrase (CA) isozymes, and AMPA/kainate receptors.
Subsequently, it was also shown to be a GABAA agonist, and that paved
the way to its use as an anticonvulsant. Although the use of TPM can
be associated with cognitive symptoms, this side effect appears to be
due to a direct effect of the drug in the CNS and is not secondary to any
metabolic abnormality. Hyperammonemia secondary to the combined
use of TPM and other antiepileptic drugs, particularly VPA, has been
reported but is probably not common, with only a few cases reported
in the literature [1–8].
3.1. Mechanism of topiramate-related hyperammonemia
To our knowledge, this is the ﬁrst case of a TPM-induced
hyperammonemia, without the use of any concurrent AEDs, to be re-
ported. Whereas the hyperammonemia seen in cases of the combina-
tion of VPA and TPM appears to be related to interference with glycine
metabolism andmetabolic acidosis, themechanism bywhich TPM itself
would cause hyperammonemia is unknown. There are two major
mechanisms that might contribute to this effect: 1) TPM is a carbonic
anhydrase inhibitor and can decrease the production of bicarbonate
(HCO3−), which is required in the synthesis of carbamoyl phosphate,
an intermediate substrate in the urea cycle, and 2) the other direct effect
of TPM is the reduction of the activity of glutamine synthetase, themain
enzyme for the detoxiﬁcation of ammonia [10].
3.2. Hyperammonemic encephalopathy
Hyperammonemic encephalopathy has been thoroughly described
in the literature. Clinical symptoms are varied and include nausea,
vomiting, seizures, ataxia, abnormal behavior, or coma, depending on
the ammonia level and age of the patient [11,12]. Venous ammonia
level may correlate less with clinical symptoms compared with arterial
ammonia level [13–15]. This patient presentedwith a two-week history
of mental status changes and psychomotor decline. He also exhibited
ataxia, nystagmus, and gait instability and one episode of complex
partial seizures during admission. The short duration of his recent
symptoms and the fact that all symptoms fully reversed indicated
that none of his recent symptomswere caused by progression of an un-
derlying CNS pathology. Other common etiologies of mental status
changes in patients with developmental delay such as toxic, metabolic,infectious, and subacute structural CNS lesions were also ruled out.
Computerized tomography scan and MRI of the brain, EEG, renal func-
tion, electrolytes, complete blood count, thyroid function, urine analysis,
and sepsis workup were all negative. The patient's EEG showed mild
slowing of the background but no epileptiform abnormalities or
triphasic waves. After discontinuation of TPM, the patient returned to
his baseline with resolution of the ataxia and nystagmus.
Although hyperammonemia may reﬂect an underlying abnormal
urea cycle defect (UCD), this did not appear to be the cause in this pa-
tient. No abnormalities suggestive of UCD had been detected in previous
evaluations looking for the etiology of his developmental delay.
Although some UCD may become manifested later in life, these cases
typically do not have developmental delay. For these reasons, we do
not believe that the development of TPM-induced hyperammonemia
was due to an “unmasking” of an underlying UCD.Conﬂict of interest
The authors declare no conﬂict of interest.References
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